

INDO-BANGLA PHARMACEUTICALS LTD

STATEMENT OF FINANCIAL POSITION


(Un-Audited)


As at 30 September 2018

Particulars	Notes	Amounts in Taka	
		30th Sep,2018	30th June,2018
ASSETS:			
Non-current Assets:			
Property, Plant and Equipment	3.00	685,877,456	654,019,821
Capital Work In Progress	4.00	680,331,536	648,473,901
		5,545,920	5,545,920
Current Assets:			
Inventories	5.00	1,059,039,068	565,947,615
Trade & Other Receivables		162,810,575	166,752,790
Advance, Deposits and Prepayments	6.00	196,420,917	188,296,158
Cash and Cash equivalents	7.00	123,383,172	119,219,048
		576,424,404	91,679,619
TOTAL ASSETS		1,744,916,524	1,219,967,436
OWNER'S EQUITY AND LIABILITIES			
Owner's Equity:			
Share Capital		1,265,290,361	1,036,100,643
Retained Earnings		930,000,000	730,000,000
		335,290,361	306,100,643
NON-CURRENT LIABILITIES			
Deferred Tax Liability		73,159,797	67,249,601
		73,159,797	67,249,601
Current Liabilities:			
Provision for WPPF		406,466,366	116,617,192
Trade Payables		9,635,018	7,576,461
IPO Refund Liability		5,589,887	6,541,572
Provision for Taxes		282,978,040	-
Liabilities for Expenses		103,645,036	97,573,822
		4,618,385	4,925,336
TOTAL OWNER'S EQUITY AND LIABILITIES		1,744,916,524	1,219,967,436
Net Asset Value (NAV) Per Share		13.20	14.19


Chief Financial Officer


Company Secretary


Director


Managing Director

Date: Dhaka

14-Nov-18



INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(Un-Audited)

For the first quarter ended 30 September 2018

Particulars	Notes	Amounts in Taka	
		30th Sep,2018	30th Sep,2017
Net Sales Revenue		165,882,809	159,230,850
Less: Cost of Sales	8.00	98,801,141	94,933,835
Gross Profit		67,081,668	64,297,016
Less: Operating Expenses:		25,802,618	24,208,839
Administrative Expenses	9.00	6,937,649	6,143,640
Selling & Distributing Expenses	10.00	18,864,969	18,065,199
Profit from Operations		41,279,049	40,088,176
Add: Non Operating Income:		1,950,635	1,975,802
Profit before Contribution to WPPF & Welfare Fund		43,229,684	42,063,978
Less: Contribution to WPPF & Welfare Fund		2,058,556	2,003,047
Profit before Tax		41,171,128	40,060,932
Less: Income Tax Expenses:		11,981,409	14,021,326
Current Tax		6,071,214	7,737,202
Deferred Tax		5,910,196	6,284,124
Net Profit for the period		29,189,718	26,039,606
Basic Earnings per share (EPS)		0.38	0.36
Diluted Earnings per share (EPS)		0.31	0.36


Chief Financial Officer


Company Secretary

 - 
Director Managing Director

Dated: Dhaka
14-Nov-18

INDO BANGLA PHARMACEUTICALS LTD
Statement of Changes in Equity
(Un-Audited)
For the first quarter ended 30th September 2018


Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2018	730,000,000	306,100,643	1,036,100,643
Issue of share Capital (IPO)	200,000,000	-	200,000,000
Net Profit for the period	-	29,189,718	29,189,718
Balance as at 30-09-2018	930,000,000	335,290,361	1,265,290,361


INDO BANGLA PHARMACEUTICALS LTD
Statement of Changes in Equity
For the first quarter ended 30th September 2017

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2017	730,000,000	207,606,643	937,606,643
Net Profit for the period	-	26,039,606	26,039,606
Balance as at 30-09-2017	730,000,000	233,646,249	963,646,249


Chief Financial Officer


Company Secretary


Director


Managing Director

Dated: Dhaka
 14-Nov-18

INDOBANGLA PHARMACEUTICALS LIMITED

Statement of Cash Flows


(Un-Audited)


For the Period ended 30th September, 2018

Particulars	Amounts in Taka	
	30th Sep, 2018	30th Sep, 2017
Cash Flow from Operating Activities		
Cash receipts from customers	157,758,050	158,675,560
Cash receipts from others income	1,950,635	2,019,912
Cash payment to Suppliers	(92,934,890)	(119,308,126)
Cash payment to Employees	(19,780,777)	(18,167,115)
Cash payment to Others	(11,337,940)	(10,122,535)
Cash Generate from operation	35,655,079	13,097,696
Cash payment against income Tax	(2,564,793)	(2,988,143)
Net Cash from Operating Activities	33,090,286	10,109,554
Cash Flow from Investing Activities		
Acquisition of property, plant and equipment	(325,140)	(423,300)
Paid for Work In Progress	-	(1,245,850)
Advance paid for L/C Margin Machinery	(24,150,400)	-
Net Cash used in Investing Activities	(24,475,540)	(1,669,150)
Cash Flow from Financing Activities		
Proceeds from issue of share capital	200,000,000	-
Cash payment to IPO Expenses	(6,848,001)	-
Receive excess of IPO Application	282,978,040	-
Net Cash from Financing Activities	476,130,039	-
Net increase in Cash and Cash equivalents	484,744,785	8,440,404
Cash and Cash Equivalents at beginning of the period	91,679,619	116,812,231
Cash and Cash Equivalent at end of the Period	576,424,404	125,252,635
Net Operating Cash Flows Per Share (NOCFPS)	0.43	0.14


Chief Financial Officer


Company Secretary


Director


Managing Director

Dated: Dhaka
14-Nov-18